Advances in proton therapy in lung cancer

Melissa A.L. Vyfhuis, Nasarachi Onyeuku, Tejan Diwanji, Sina Mossahebi, Neha P. Amin, Shahed N. Badiyan, Pranshu Mohindra, Charles B. Simone

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Lung cancer remains the leading cause of cancer deaths in the United States (US) and worldwide. Radiation therapy is a mainstay in the treatment of locally advanced non-small cell lung cancer (NSCLC) and serves as an excellent alternative for early stage patients who are medically inoperable or who decline surgery. Proton therapy has been shown to offer a significant dosimetric advantage in NSCLC patients over photon therapy, with a decrease in dose to vital organs at risk (OARs) including the heart, lungs and esophagus. This in turn, can lead to a decrease in acute and late toxicities in a population already predisposed to lung and cardiac injury. Here, we present a review on proton treatment techniques, studies, clinical outcomes and toxicities associated with treating both early stage and locally advanced NSCLC.

Original languageEnglish
JournalTherapeutic Advances in Respiratory Disease
StatePublished - Jul 14 2018


  • non-small cell lung cancer
  • pencil beam scanning
  • proton therapy
  • radiation therapy
  • toxicities


Dive into the research topics of 'Advances in proton therapy in lung cancer'. Together they form a unique fingerprint.

Cite this